rs267608050
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.1784delT(p.Leu595TyrfsTer15) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,884 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461884Hom.: 0 Cov.: 34 AF XY: 0.00000138 AC XY: 1AN XY: 727244
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 5 Pathogenic:1
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
Lynch syndrome Pathogenic:1
Coding sequence variation resulting in a stop codon -
not provided Pathogenic:1
- -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 89223). This premature translational stop signal has been observed in individual(s) with colorectal cancer (PMID: 22081473). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Leu595Tyrfs*15) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.1784delT pathogenic mutation, located in coding exon 4 of the MSH6 gene, results from a deletion of one nucleotide at nucleotide position 1784, causing a translational frameshift with a predicted alternate stop codon. This variant has been reported in multiple individuals and families with Lynch syndrome; some of whom have tumor testing results showing high microsatellite instability and loss of the MSH6 protein via immunohistochemical staining and/or who meet Amsterdam II and/or revised Bethesda criteria (Wijnen J et al. Nat. Genet., 1999 Oct;23:142-4; van Lier MG et al. J. Pathol., 2012 Apr;226:764-74; Baglietto L et al. J. Natl. Cancer Inst., 2010 Feb;102:193-201; Ramsoekh D et al. Gut, 2008 Nov;57:1539-44). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at